Biocon has bagged a MYR 300 million (about INR 4,605 million) contract from the Ministry of Health, Malaysia, to supply recombinant human insulin formulations for a period of three years. The drug, manufactured by Biocon at its scale bio-pharmaceutical facility in Johor, Malaysia. The contract is extendable for an additional two years period subject to approval by the Government of Malaysia. Biocon will distribute insulins and insulin delivery devices through Malaysia’s CCM Pharmaceuticals.